There has been inadequate evaluation of an antibiotic for eradication of nontyphoidal salmonellae (NTS) in asymptomatic carriers. In a randomized, placebo-controlled trial, such efficacy was evaluated using 2 five-day regimens (norfloxacin, 400 mg twice per day, and azithromycin, 500 mg once per day) compared with placebo. The study included 265 food workers in an area of Thailand where NTS are endemic who were asymptomatic NTS carriers. The presence of NTS in stool samples was assessed on days 7, 30, 60, and 90 after start of treatment. At each assessment visit, !4% of participants in each of the 3 groups carried an initial Salmonella serotype; 16%-35% had new Salmonella serotypes detected, except on day 7 in the azithromycin group, when the rate was 4%. Sanitation was good at work but not at home. Selection of multidrug-resistant Salmonella enterica serotype Schwarzengrund was demonstrated. The study regimens were not better than placebo for treatment of asymptomatic food workers who carried NTS in an area where these organisms are endemic, and use of the regimens resulted in antimicrobial resistance.
Salmonella infection associated with food products is the most frequently identified cause of foodborne outbreaks of disease, and the usual source of contamination is raw food of animal origin [1] . Although asymptomatic nontyphoidal salmonellae (NTS) excretion in the general population rarely causes spreading of salmonellae, food workers generally are considered to be potential sources. When contamination of commercial food occurs, significant public health problems and significant economic loss normally follow. In many locations worldwide, routine screening for NTS carriage and giving an antibiotic to asymptomatic food workers infected with NTS are common practices. The efficacy of antimicrobial therapy for asymptomatic NTS carriage has never been adequately established; therefore, there is no strong evidence to guide clinical practice for antibiotic treatment. In addition, efficacy of any new drugs should be investigated.
Success in antimicrobial treatment for eradicating intestinal salmonellae has been suggested from case reports [2, 3] and uncontrolled studies [4] [5] [6] [7] [8] involving aztreonam [2] , ofloxacin [3] , norfloxacin [4] , pefloxacin [5] , and ciprofloxacin [6] [7] [8] , but there also have been reports of failure with ceftriaxone [9] and ciprofloxacin [10] . However, comparative observational studies [11] [12] [13] [14] [15] [16] and a systematic review [17] of randomized, controlled trials [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] show that antimicrobial therapy has no effect on intestinal NTS in patients with diarrhea and may even cause prolonged excretion and emergence of drug-resistant bacteria. In a review of 15 controlled trials [17] , only 3 [26] [27] [28] included asymptomatic NTS carriers (all without data for subgroup analyses), accounting for only 7% of the participants in the review.
Norfloxacin, a potentially effective quinolone [29, 30] , is commonly used to treat intestinal NTS infection. Azithromycin, a more recently available antimicrobial drug, has an in vitro effect against salmonellae [31] , is noted for its intracellular activity and extended tissue-elimination half-life [32, 33] , and has been reported to be an effective drug for treatment of typhoidal Salmonella infection [34, 35] . However, to our knowledge, there has been only 1 study of the effect of azithromycin on intestinal NTS, and it involved children with acute NTS enteritis [36] .
Our purpose in the present study was to identify evidence supporting the use of antibiotics to treat NTS carriers and to assist health care administrators in establishing a policy for treatment of food workers with NTS carriage. This study evaluated the efficacy of norfloxacin and azithromycin regimens in treatment of asymptomatic NTS carriage in healthy adults who were working in food-processing factories. The study also explored the effects of antimicrobial treatment on drug resistance.
METHODS

Study population.
The study was conducted in 4 food factories in an area of Thailand where NTS is endemic. The workers are routinely checked for enteric pathogens, and Salmonella carriers are commonly treated with an antimicrobial regimen. Informed consent was obtained from each worker before a pretreatment rectal swab specimen was obtained. NTS-positive workers were offered participation in the trial. Pregnant or breast-feeding women and persons with diarrhea, any illness, or history of quinolone or macrolide intolerance were excluded. Persons who had taken an antibacterial drug р2 weeks before the rectal swab specimen was obtained also were excluded.
Study design and treatment regimens. The Ethics Committee of the Ministry of Public Health, Nonthaburi, Thailand, approved the study protocol. The study was a randomized, double-blind, placebo-controlled trial. Three 5-day regimens were used, as follows: (1) two 200-mg norfloxacin (Lexinor; Astra) tablets twice per day, (2) two 250-mg azithromycin (Zithromax, Pfizer) tablets in the morning plus 2 azithromycin placebo tablets in the evening, and (3) placebo. One-half of the third group received 2 placebo tablets twice per day in lieu of norfloxacin, and one-half received 2 placebo tablets twice per day in lieu of azithromycin.
Each trial participant was given an identification number. Participants at each factory were randomly assigned by computer in a 1:1:1 ratio to receive 1 of the 3 regimens. The participants assigned to receive placebo were randomized to receive either norfloxacin placebo or azithromycin placebo, but data for these persons were combined into 1 placebo group for analysis. Each participant's identification number was placed on a set of 2 opaque envelopes containing the tablets for the individual regimen; one envelope was for the morning dose, and the other was for the evening dose. Randomization and preparation of the study drugs or placebo for administration were done by an author (J.T.) who was not involved with either drug administration or outcome measurement.
The treatment was begun 5 days after the pretreatment rectal swab specimen was obtained. The study drug or placebo was given to each participant for 5 days (days 1-5) at the daily medication times (∼12 h apart) and was immediately taken by the participant in the presence of a research assistant. The research assistants who gave medicine to the participants had been informed about the medication procedure but were not involved in any other part of the trial.
Microbiological investigation. Three research assistants responsible for obtaining a rectal swab followed a standardized technique. The swab was transported in Cary-Blair transport medium with coding to the laboratory. Laboratory personnel were unaware of any information about the trial participants. All rectal swab specimens were processed within 24 h.
All microbiological tests and Salmonella serotyping were performed at the National Salmonella and Shigella Center, Department of Medical Science, Ministry of Public Health (Nonthaburi, Thailand). This center is a World Health Organization (WHO) Global Salm-Surv laboratory and has been accredited by the External Quality Assurance System, which is organized by the Danish Veterinary Institute, Copenhagen, in collaboration with the WHO and the Centers for Disease Control and Prevention.
All media and test reagents used in this study were manufactured by Mast Diagnostics, with the exception of antisera for NTS detection and serotyping (Serotest; S & A Reagent Laboratory Limited, Bangkok). Serotest antisera were qualitychecked by the Danish Veterinary Institute and Institut Pasteur (Paris) and are approved for use in several WHO Collaborating Centers for Resistance in Food-Borne Pathogens. Antibiotic discs were manufactured by Oxoid Diagnostics.
Each Salmonella isolate was serotyped by a combination of the O and H reactions, and then the serotype was identified by the Kauffman-White serotyping scheme [37] . Antimicrobial susceptibility was determined by disk diffusion on MuellerHinton agar following guidelines published by the United States NCCLS [38, 39] . The interpretative zone size breakpoint was р12 mm for norfloxacin, р13 mm for azithromycin, р13 mm for ampicillin, р14 mm for cefotaxime, р10 mm for trimethoprim-sulfamethoxazole (TMP-SMZ), and р14 mm for tetracycline.
Outcome assessment. A rectal swab specimen was obtained from each participant and cultured on days 7, 30, 60, and 90. Each participant was interviewed by a research assistant at each visit for medication and also at the first posttreatment visit (day 7) concerning side effects associated with the drug and any illnesses.
Statistical methods. Sample size estimation was based on NTS infection rate in the target population of 11%, an efficacy (24) 23 (24) 24 (25) 20 (21) Mon 29 (10) 10 (11) 5 (5) 14 (15) Employment site Factory A 79 (28) 26 (28) 27 (28) 26 (27) 1.000
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1-2 85 (30) 34 (36) 28 (29) 23 (24) 3-4 54 (19) 14 (15) 19 (20) 21 (22) 15 54 (19) 14 (15) 21 (22) 19 (20) NOTE. Data are no. (%) of participants, unless otherwise indicated.
rate with treatment of 10%, a error of 0.05, and b error of 0.8. The sample size needed for each group was 87. We expected that 10% of the trial population would be lost to follow-up; therefore, we planned to enroll 96 persons for each treatment group. STATA statistical software (StataCorp) was used for all calculations [40] . Either the x 2 test or Fisher's exact test (for expected cell frequencies of !5) was used for univariate examination of categorical data. Continuous variables that were not normally distributed were described using median and range and were analyzed with the Kruskal-Wallis test for comparing 12 groups. A significant difference between the compared groups was assumed if P was !.05. All P values were 2-tailed.
RESULTS
Of 3209 food workers at 4 factories, 308 (10%) had NTS detected. Twenty-three NTS carriers were disqualified (17 did not give consent, 2 had diarrhea, 2 had an underlying disease, 1 was pregnant, and 1 had received an antimicrobial drug р2 weeks earlier). A total of 285 NTS carriers were eligible to participate in the trial; 4 each had NTS isolates of 2 different serotypes. Twelve participants had also another enteric bacterial pathogen isolated (Vibrio parahaemolyticus in 9 participants and non-O1/O139 Vibrio cholerae in 3).
Twenty participants did not complete the 5-day study regimens (absence from work, for 15 participants; subject quit job, for 4; and intolerability of side effects of norfloxacin, for 1). A total of 265 (93%) of 285 participants completed the regimens. Thirty-five participants missed у1 follow-up assessment visit (subject quit job and follow-up not possible, for 32 participants; receipt of another antimicrobial drug, for 3). As a consequence, the numbers of trial participants on assessment days 7, 30, 60, and 90 were 257, 244, 239, and 230, respectively. There were no statistically significant differences between the 3 treatment groups with regard to the proportion of participants who were excluded from follow-up assessment at any of the 4 assessment visits ( , , , and for days 7, 30, P p .31 P p .87 P p .60 P p .31 60, and 90, respectively).
There were no statistically significant differences between the 3 treatment groups with regard to baseline characteristics (table  1) . The bacteriological findings (serotype distribution and antimicrobial susceptibility pattern of NTS isolates from pretreatment cultures, as well as proportions of participants with coinfection) were comparable among the 3 treatment groups. The Salmonella isolates recovered from the participants at enrollment were of 42 serotypes, the 2 most common of which were Salmonella enterica serotype Anatum and S. enterica serotype Rissen, which accounted for 95 (33%) of the 289 isolates (table 2). On posttreatment day 90 at factory B, the prevalence of NTS excretors was 28% (23 of 83 participants) among food workers who were in the trial; the prevalence was 12% (53 of 424 participants) among food workers who had had negative results of pretreatment cultures ( ), whereas the pretreatment P ! .001 prevalence of asymptomatic NTS carriage at factory B was 10% (107 of 1099).
The rates of resistance of salmonellae to norfloxacin and azithromycin found in pretreatment and follow-up cultures are presented in table 4. In the norfloxacin group on day 7, the norfloxacin-resistance rate was 50% (8 of 16 isolates), which was higher than the rate in the placebo group ( ); however, the rate for norflox-P ! .001 acin resistance was 0% on days 30, 60, and 90. On day 7, the proportion of azithromycin-resistant isolates (1 of 3) in the azithromycin group was too small for statistical comparison, but the 50% rate (8 of 16) in the norfloxacin group was not significantly different from the 24% rate (5 of 21) in the placebo group ( ). Between the pretreatment period and day 7, the P p .165 overall norfloxacin-resistance rate increased from 1% (2 of 289) to 22% (9 of 40; ), and the azithromycin-resistance rate P ! .001 increased from 7% (21 of 289) to 35% (14 of 40; P ! .001).
All 8 norfloxacin-and azithromycin-resistant NTS isolates detected on day 7 in norfloxacin group were S. enterica serotype Schwarzengrund. Thirteen (52%) of the total of 25 S. Schwarzengrund isolates in this study were resistant to norfloxacin, azithromycin, ampicillin, TMP-SMZ, and tetracycline but were susceptible to cefotaxime. Multidrug-resistant S. Schwarzengrund accounted for 13 (87%) of all 15 norfloxacin-resistant isolates. Patterns of antimicrobial resistance were not remarkable with regard to other NTS serotypes.
Adverse drug reactions were reported by 23 (24%) of 94 norfloxacin recipients, 18 (19%) of 95 azithromycin recipients, and 15 (16%) of 96 placebo recipients ( ). They in-P p 0.30 cluded minimal symptoms of dizziness, nausea, and abdominal discomfort. One norfloxacin recipient had vomiting and withdrew from the trial.
DISCUSSION
This study demonstrates that neither norfloxacin nor azithromycin treatment for 5 days is better than placebo for eradicating intestinal NTS carriage in healthy asymptomatic adults in an area of Thailand where NTS is endemic. Prolonged excretion of NTS caused by antimicrobial therapy was not seen, but each of the 3 treatment groups had a high rate of reinfection with new salmonellae. Selection of norfloxacin-and azithromycin-resistant S. Schwarzengrund by norfloxacin treatment was demonstrated.
A stool specimen more likely will yield an NTS-positive culture than will a rectal swab specimen. Assessment by stool specimen was not appropriate for our study, which included a large group of asymptomatic participants. Our study might slightly underdetect NTS carriage, but the comparability of bacteriological assessment among the 3 treatment groups was maintained.
Our study agrees with a previous report by Chiu et al. [36] that azithromycin is no better than placebo for treatment of intestinal NTS infection. Almost all participants (у98%) in each treatment group had eradicated their initial NTS infection at day 12 after pretreatment bacteriological screening (or at day 7 after the start of treatment), making the duration of NTS excretion shorter for our study population than has been reported elsewhere [11] [12] [13] [14] 41] . The duration of convalescent NTS carriage varies with host factors, Salmonella serotype, patient entry point, and the criteria used for determining Salmonella eradication [41] . Our study participants were all healthy, adult, asymptomatic carriers who lived in an area of endemicity and whose onset of NTS infection was unknown; to our knowledge, there have been no previous studies involving such a population.
Reinfection was assumed when an NTS serotype detected in an assessment culture was different from that found in the pretreatment culture. The reinfection rate was high, and reinfection occurred early. The exceptionally low reinfection rate (3 [4%] of 85 participants) in the azithromycin group on day 7 could be the result of a longer suppressive effect resulting from azithromycin's extended tissue-elimination half-life. Although rectal swabs might have missed some preexisting NTS serotypes, this effect should be considered minimal in comparison to the high rates of detection of new serotypes. The finding of a higher NTS infection rate at factory B on day 90 in the trial participants than the pretreatment culture-negative workers suggested higher risks for NTS infection among the study participants than among the workers not included in the study. By visiting the factories and living places of the workers, it was found that food workers at each of the 4 factories had excellent hygiene and sanitation at their work place, but sanitation in their domiciles was poor. Our findings were well accepted by the factory managers. The NTS-infected workers were moved to work in another department not involved with food processing. Routine screening for NTS was continued using local facilities, but antimicrobial therapy was not given. They were helped to improve their sanitation and hygiene. An increase in the proportion of norfloxacin-and azithromycin-resistant S. Schwarzengrund isolates (from 1 [1%] of 95 pretreatment isolates to 8 [50%] of 16 isolates on day 7) in the norfloxacin group was probably caused by selective pressure from norfloxacin treatment. Participants were not in the same cluster, suggesting that it was not a local outbreak. One report of a nosocomial outbreak of quinolone-resistant S. Schwarzengrund identified previous exposure to a quinolone drug as a risk factor for infection [42] . A study from Vietnam and Thailand found progressive resistance to quinolones and coresistance between quinolones and azithromycin among salmonellae and Campylobacter species [43] .
Although there was an increase in the overall rate of azithromycin resistance on day 7 (14 [35%] of 40 isolates), compared with the pretreatment rate (21 [7%] of 289), the number of NTS isolates ( ) in the azithromycin group was too small n p 3 for comparison among treatment groups. In addition, interpretation of azithromycin susceptibility is problematic, because the intracellular activity is more prominent than in other drugs [32, 33] . Therefore, the effect of azithromycin treatment on the selection of an azithromycin-resistant isolate is difficult to interpret.
Five-day treatment with norfloxacin or azithromycin is not the solution for NTS carriage. Because NTS naturally disappears within 2 weeks in most healthy, adult, convalescent carriers, and because receipt of antimicrobial treatment results in the emergence of antimicrobial-resistant bacteria, administration of an antimicrobial drug is inappropriate. Good sanitation and adequate hygiene are important for both prevention of acquisition and control of spreading. Antibiotic treatment of NTS carriers cannot be expected to prevent reinfections in an area where NTS is endemic.
